Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Milutinovic, Pavle S ^a   Englert, Judson M ^b   Crum, Lauren T ^a   Mason, Neale S ^a   Ramsgaard, Lasse ^c   Enghild, Jan J ^c   Sparvero, Louis J ^d   Lotze, Michael T ^d   Oury, Tim D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; LAMININ; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; PROTEIN BINDING;

AMINO ACID ANALYSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CLEARANCE; CONTROLLED STUDY; DISEASE MODEL; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; INTRAVENOUS ADMINISTRATION; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TISSUE DISTRIBUTION; ANIMAL; BIOAVAILABILITY; C57BL MOUSE; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; KINETICS; LUNG; METABOLISM; SOLUBILITY;

ADMINISTRATION, INHALATION; ANIMALS; BIOLOGICAL AVAILABILITY; COLLAGEN TYPE I; COLLAGEN TYPE IV; FIBRONECTINS; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; KINETICS; LAMININ; LUNG; MALE; MICE; MICE, INBRED C57BL; PROTEIN BINDING; RECEPTORS, IMMUNOLOGIC; SOLUBILITY;

EID: 84898621243     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088259     Document Type: Article

References (50)

1. Vlassara H, Brownlee M, Cerami A (1988) Specific macrophage receptor activity for advanced glycosylation end products inversely correla (Pubitemid 18096384)
2. Vlassara H, Moldawer L, Chan B (1989) Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. J Clin Invest 84: 1813-1820. (Pubitemid 20016185)
3. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, et al. (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 91: 7742-7746.
4. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004.
5. Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10: 209.
6. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A (2008) HMGB1: endogenous danger signaling. Mol Med 14: 476-484.
7. Du Yan S, Zhu H, Fu J, Yan SF, Roher A, et al. (1997) Amyloid-beta peptidereceptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A 94: 5296-5301. (Pubitemid 27214777)
8. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR (2008) S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 102: 1239-1246.
9. Steiner J, Bogerts B, Schroeter ML, Bernstein HG (2011) S100B protein in neurodegenerative disorders. Clin Chem Lab Med 49: 409-424.
10. Volz HC, Laohachewin D, Seidel C, Lasitschka F, Keilbach K, et al. (2012) S100A8/A9 aggravates post-ischemic heart failure through activation of RAGEdependent NF-kappaB signaling. Basic Res Cardiol 107: 250.
11. Frommhold D, Kamphues A, Dannenberg S, Buschmann K, Zablotskaya V, et al. (2010) RAGE and ICAM-1 differentially control leukocyte recruitment during acute inflammation in a stimulus-dependent manner. BMC Immunol 12: 56.
12. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, et al. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712. (Pubitemid 24058273)
13. Teismann P, Sathe K, Bierhaus A, Leng L, Martin HL, et al. (2012) Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging 33: 2478-2490.
14. Kataoka K, Ono T, Murata H, Morishita M, Yamamoto KI, et al. (2012) S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products. Oncol Lett 3: 1149-1153.
15. Miller AL, Sims GP, Brewah YA, Rebelatto MC, Kearley J, et al. (2012) Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection. J Infect Dis 205: 1311-1320.
16. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, et al. (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83: 876-886. (Pubitemid 41598688)
17. Marsche G, Weigle B, Sattler W, Malle E (2007) Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein. FASEB J 21: 3075-3082. (Pubitemid 47565528)
18. Chuong C, Katz J, Pauley KM, Bulosan M, Cha S (2009) RAGE expression and NF-kappaB activation attenuated by extracellular domain of RAGE in human salivary gland cell line. J Cell Physiol 221: 430-434.
19. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, et al. (2008) A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 172: 583-591. (Pubitemid 351354532)
20. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, et al. (2005) Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 18: 1385-1396. (Pubitemid 41348659)
21. Dahlin K, Mager EM, Allen L, Tigue Z, Goodglick L, et al. (2004) Identification of genes differentially expressed in rat alveolar type I cells. Am J Respir Cell Mol Biol 31: 309-316. (Pubitemid 39180300)
22. Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, et al. (1998) Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand) 44: 1147-1157.
23. Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, et al. (2004) Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells 9: 165-174. (Pubitemid 38312960)
24. Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, et al. (2006) Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 323: 475-488. (Pubitemid 43228103)
25. Goova MT, Li J, Kislinger T, Qu W, Lu Y, et al. (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 159: 513-525. (Pubitemid 32751082)
26. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, et al. (2008) The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 28: 12023-12031.
27. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A (2006) Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 54: 3898-3907. (Pubitemid 44955893)
28. Schmidt AM, Yan SD, Wautier JL, Stern D (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84: 489-497. (Pubitemid 29138585)
29. Sourris KC, Morley AL, Koitka A, Samuel P, Coughlan MT, et al. (2010) Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 53: 2442-2451.
30. Sternberg DI, Gowda R, Mehra D, Qu W, Weinberg A, et al. (2008) Blockade of receptor for advanced glycation end product attenuates pulmonary reperfusion injury in mice. J Thorac Cardiovasc Surg 136: 1576-1585.
31. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, et al. (2006) RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185: 70-77. (Pubitemid 43117552)
32. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, et al. (2004) Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 39: 422-432. (Pubitemid 38222183)
33. Ramasamy R, Yan SF, Schmidt AM (2009) RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 86: 505-512.
34. Englert JM, Ramsgaard L, Valnickova Z, Enghild JJ, Oury TD (2008) Large scale isolation and purification of soluble RAGE from lung tissue. Protein Expr Purif 61: 99-101.
35. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, et al. (2004) Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 279: 50019-50024. (Pubitemid 39577812)
36. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/ calgranulin polypeptides. Cell 97: 889-901. (Pubitemid 29375048)
37. Abdiche Y, Malashock D, Pinkerton A, Pons J (2008) Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet. Anal Biochem 377: 209-217.
38. Do T, Ho F, Heidecker B, Witte K, Chang L, et al. (2008) A rapid method for determining dynamic binding capacity of resins for the purification of proteins. Protein Expr Purif 60: 147-150.
39. Xie J, Burz DS, He W, Bronstein IB, Lednev I, et al. (2007) Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 282: 4218-4231. (Pubitemid 47084493)
40. Sarkany Z, Ikonen TP, Ferreira-da-Silva F, Saraiva MJ, Svergun D, et al. (2011) Solution structure of the soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 286: 37525-37534.
41. Andrews P (1970) Estimation of molecular size and molecular weights of biological compounds by gel filtration. Methods Biochem Anal 18: 1-53.
42. Rippe B (1993) A three-pore model of peritoneal transport. Perit Dial Int 13 Suppl 2: S35-38. (Pubitemid 23261137)
43. Zhang H, Tasaka S, Shiraishi Y, Fukunaga K, Yamada W, et al. (2008) Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 178: 356-362.
44. Mizumoto S, Takahashi J, Sugahara K (2012) Receptor for advanced glycation end products (RAGE) functions as receptor for specific sulfated glycosaminoglycans, and anti-RAGE antibody or sulfated glycosaminoglycans delivered in vivo inhibit pulmonary metastasis of tumor cells. J Biol Chem 287: 18985-18994.
45. Englert J (2009) A pathophysiologic evaluation of the receptor for advanced glycation end products (RAGE) in the lung [Ph.D.]. United States - Pennsylvania: University of Pittsburgh. 163 p.
46. Hastings RH, Grady M, Sakuma T, Matthay MA (1992) Clearance of differentsized proteins from the alveolar space in humans and rabbits. J Appl Physiol 73: 1310-1316.
47. Effros RM, Mason GR (1983) Measurements of pulmonary epithelial permeability in vivo. Am Rev Respir Dis 127: S59-65. (Pubitemid 13103650)
48. John TA, Vogel SM, Minshall RD, Ridge K, Tiruppathi C, et al. (2001) Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J Physiol 533: 547-559. (Pubitemid 32520007)
49. Hastings RH, Folkesson HG, Matthay MA (2004) Mechanisms of alveolar protein clearance in the intact lung. Am J Physiol Lung Cell Mol Physiol 286: L679-689. (Pubitemid 38365050)
50. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4: 2411-2423.